Navigation Links
Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
Date:2/20/2008

Dr. Bill Poland Will Discuss Best Practices in HCV and HIV Drug-Disease Modeling and Simulation to Support Clinical Drug Development Decision

Making

MOUNTAIN VIEW, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries via web conference on HCV/HIV drug-disease modeling on Thursday, February 28, 2008, at 1:00 p.m. Eastern Standard Time (10:00 a.m. PST).

Dr. Poland's presentation, entitled "Portable Concepts for HCV and HIV Drug-Disease Modeling and Simulation" will discuss the use and strategic value of quantitative modeling and simulation to design, predict and improve clinical trial outcomes for HCV and HIV drugs. Applied case examples will illustrate that despite important differences between HCV and HIV, such as the potential to cure HCV and faster HCV dynamics, HCV trial outcomes, like those for HIV, can be predicted and improved by model-informed design. More information about this event is available at http://www.pharsight.com/events/events_home.php.

"HCV and HIV present special therapeutic challenges to drug development teams, including the emergence of resistance, complex pharmacokinetics, and patient compliance," said Shawn O'Connor, president, CEO and chairman of Pharsight. "To support planning and quantitative decision-making for antiviral development, it is important to leverage synergies wherever possible in the complexities of viral dynamics modeling. HIV and HCV drug development programs can benefit from Pharsight's predictive modeling methods and extensive knowledge of the competitive treatment landscape. Model-based approaches can lead to enhanced clinical trial designs and in developing strategies to optimize tradeoffs such as that between patient compliance and dosing regimen, as well as inform better clinical program investment decisions."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA and Pharsight Continue to Collaborate Under CRADA
2. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
3. Pharsight Achieves $7.3 Million in Quarterly Revenue
4. Pharsight Expands Global Consulting Services Teams
5. Pharsight to Host European Software Conference
6. Pharsight Files Application for Nasdaq Capital Market Listing
7. FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges
8. Portico Systems Offers Webinar Series to Share Provider Network Management Best Practices
9. Uncover Key Competitive Intelligence Insights in Webinars Hosted by Best Practices
10. GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
11. Grapefruit compound may help combat hepatitis C infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Today, ... optimize the ingestion of their medication by matching users with high quality water pipes ... compare pieces with no commitment. , Inhale was founded by two brothers, Nick and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Blood Supply Foundation, a not-for-profit organization responsible for clinical transfusion research programs and ... enrollment for the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. ...
(Date:6/23/2016)... TX (PRWEB) , ... June 23, 2016 , ... The ... and business clients throughout Jasper County and the surrounding region, is initiating a charity ... charity drive will raise funds earmarked for a scholarship fund that will be presented ...
(Date:6/23/2016)... ... 23, 2016 , ... Representatives of CHA Fertility Centers (CFC), one of the ... Dr. Joshua J. Berger. As of May 2016, Dr. Berger will serve as ... Berger has received recognition for his research, his teaching and his patient care. After ...
(Date:6/23/2016)... ... June 23, 2016 , ... The U.S. Supreme Court decision on immigration ... by The Senior Citizens League (TSCL) . “President Obama’s executive actions on ... for people who worked in this country illegally, even though the newly - issued ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... 23, 2016 The Biotechnology industry ... to present great opportunities to investors. Stock-Callers.com assesses the ... Corp. (NYSE: XON ), Vertex Pharmaceuticals Inc. ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... and receive your complimentary trade alerts at: ...
(Date:6/23/2016)... 2016 Research and Markets has ... 2016 Edition: The New Global Agenda " report to ... Distribution in Europe - the 2016 ... tracks change. It identifies the driving factors coming into play ... healthcare industry now and in the future. It provides a ...
Breaking Medicine Technology: